|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0012655,
umls-concept:C0023779,
umls-concept:C0023823,
umls-concept:C0037903,
umls-concept:C0053574,
umls-concept:C0205217,
umls-concept:C0205349,
umls-concept:C0486616,
umls-concept:C0870432,
umls-concept:C1167622,
umls-concept:C1555465,
umls-concept:C1705417
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-9-1
|
|
pubmed:abstractText |
Apolipoprotein CIII (apoCIII) is an independent risk factor for cardiovascular disease, but the molecular mechanisms involved are poorly understood. We investigated potential proatherogenic properties of apoCIII-containing LDL from hypertriglyceridemic patients with type 2 diabetes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoprotein C-III,
http://linkedlifedata.com/resource/pubmed/chemical/Apolipoproteins B,
http://linkedlifedata.com/resource/pubmed/chemical/BGN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bgn protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Biglycan,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Matrix Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Sphingomyelin Phosphodiesterase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1939-327X
|
|
pubmed:author |
pubmed-author:AdielsMartinM,
pubmed-author:BorénJanJ,
pubmed-author:EkroosKimK,
pubmed-author:HiukkaAnneA,
pubmed-author:HulténLillemor MattssonLM,
pubmed-author:LevinMalinM,
pubmed-author:OlofssonSven-OlofSO,
pubmed-author:OresicMatejM,
pubmed-author:PetterssonCamillaC,
pubmed-author:SchollmeyerJ EJE,
pubmed-author:StåhlmanMarcusM,
pubmed-author:TaskinenMarja-RiittaMR,
pubmed-author:TenebergSusanneS,
pubmed-author:WiklundOlovO
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2018-26
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19502413-Aged,
pubmed-meshheading:19502413-Animals,
pubmed-meshheading:19502413-Apolipoprotein C-III,
pubmed-meshheading:19502413-Apolipoproteins B,
pubmed-meshheading:19502413-Biglycan,
pubmed-meshheading:19502413-Cells, Cultured,
pubmed-meshheading:19502413-Diabetes Mellitus, Type 2,
pubmed-meshheading:19502413-Endothelial Cells,
pubmed-meshheading:19502413-Extracellular Matrix Proteins,
pubmed-meshheading:19502413-Female,
pubmed-meshheading:19502413-Humans,
pubmed-meshheading:19502413-Hydrolysis,
pubmed-meshheading:19502413-Hypertriglyceridemia,
pubmed-meshheading:19502413-Lipoproteins, LDL,
pubmed-meshheading:19502413-Male,
pubmed-meshheading:19502413-Mice,
pubmed-meshheading:19502413-Mice, Transgenic,
pubmed-meshheading:19502413-Middle Aged,
pubmed-meshheading:19502413-Proteoglycans,
pubmed-meshheading:19502413-Risk Factors,
pubmed-meshheading:19502413-Sphingomyelin Phosphodiesterase
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.
|
|
pubmed:affiliation |
Department of Medicine, Helsinki University Central Hospital and Biomedicum, Helsinki, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
